Project Grant K22CA282264
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$194K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $145,336 Project Grant under its Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research, a leading non-profit cancer research organization in New York. The award, effective from March 1, 2025 to February 28, 2027, will support research to determine whether and how metabolically reprogramming hepatic macrophages, a type of immune cell, can overcome the "immune-desert" phenotype of liver cancers...
The National Cancer Institute (NCI) awarded a $281,370 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Ohio State University to conduct research aimed at overcoming resistance to immunotherapy in lung cancers with STK11 mutations. The key objectives of this 5-year award are to: 1) characterize the relationship between tumor differentiation phenotypes, immune microenvironment, and response to immune checkpoint blockade; and 2) understand the role of the TRAF2/cIAP1...
The National Cancer Institute (NCI) awarded a $392,410 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University. The grant funds a 3-year research project titled "Targeting Drivers of Tumor Heterogeneity to Block the Progression to Neuroendocrine Prostate Cancer." The project aims to use a novel mouse model and organoid-based platform to identify key transcriptional regulators driving the transition from prostate...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
The National Cancer Institute (NCI) awarded a $293,369 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Duke University to investigate the mechanisms by which residual tumor cells evade the immune system after treatment with oncogene-targeted therapies. The grant will fund a series of integrative transcriptomics and functional genomics studies to uncover potential mechanisms to target and engineer the immune-mediated clearance of residual tumor cells. The research aims to elucidate...
The National Cancer Institute (CFDA 93.398 Cancer Research Manpower) awarded a $183,398 Project Grant to The Ohio State University, with a start date of September 1, 2024 and an end date of August 31, 2027. The grant is titled "Targeting Mitochondrial Oxygen Demand to Overcome Hypoxic Immune Privilege of NSCLC Tumors" and aims to elucidate the mechanisms of hypoxic immune privilege in non-small cell lung cancer (NSCLC) tumors. The research will investigate how targeting tumor hypoxia...
The National Cancer Institute (NCI) awarded a $509,448 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Leland Stanford Junior University. The grant supports research to identify the antigen-presenting cell (APC) population responsible for inducing tumor-specific regulatory T cells that promote metastatic progression, and to develop immunotherapeutic strategies to reprogram APCs and overcome tumor immune tolerance. The research aims to delineate the key...
This Project Grant award, funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports research to investigate the mechanisms by which MEK signaling inhibition can lead to the regression of papillomavirus-induced tumors. The $544,768 award to the University of New Mexico Health Sciences Center will be used to conduct a 5-year study with the following key objectives: Ascertain how MEK inhibition alters the intrinsic antiviral responses of keratinocytes (skin cells) in...
This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $695,610 in funding to The Washington University in St. Louis over a 5-year period beginning June 12, 2024. The award will support a research project titled "Lung Fibrosis Impairs Tumor Immunity and Limits Immune Checkpoint Efficacy". The project aims to investigate how fibrosis in the tumor microenvironment impairs T-cell priming and antigen trafficking/presentation, and how...